CureVac raises equity to fund Covid-19 vaccine rollout
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
EquityABBs-Block Trades

CureVac raises equity to fund Covid-19 vaccine rollout

CureVac_2_575_375

CureVac, the German biotechnology company, has launched a $523m share sale to fund late stage clinical trials for its Covid-19 vaccine, and an expansion of its manufacturing capacity.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article